Connection

Saul Faust to Immunogenicity, Vaccine

Back to Details
This is a "connection" page, showing publications Saul Faust has written about Immunogenicity, Vaccine.
Saul Faust
Connection Strength
0.279
Immunogenicity, Vaccine
  1. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021 09 04; 398(10303):856-869.
    View in: PubMed
    Score: 0.075
  2. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021 12 19; 396(10267):1979-1993.
    View in: PubMed
    Score: 0.072
  3. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 08 15; 396(10249):467-478.
    View in: PubMed
    Score: 0.070
  4. Meningococcal B Vaccine Immunogenicity in Children With Defects in Complement and Splenic Function. Pediatrics. 2018 09; 142(3).
    View in: PubMed
    Score: 0.061
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.